WASHINGTON, DC — US biotech firm Novavax said on Monday it had started clinical trials of its proposed COVID-19 vaccine on children, in a program that will involve up to 3,000 adolescents aged 12–17.
Far fewer children have been sick with COVID-19 compared to adults, and most have mild to no symptoms, but they can be infected and spread the virus.
Novavax said the trials would test “the efficacy (and) safety” of the vaccine, with participants receiving either the vaccine candidate or placebo in two doses, 21 days apart.
Participants will be monitored for up to two years after their injections.
The Novavax vaccine has not yet been authorized in any country, including for adults, but the company plans to file for emergency authorization in Britain “in the second quarter of 2021”, followed by in the United States.
Novavax announced at the end of January that clinical trials conducted in Britain involving 15,000 adults showed 89.3 percent efficacy.
The Novavax vaccine, which uses different technology from the doses already widely licensed around the world, is a protein-based vaccine engineered from the genetic sequence of the first strain of the coronavirus.
It can be stored at a temperature between 2–8°C.
Other vaccine companies including Moderna, Johnson & Johnson and Pfizer are also conducting trials in adolescents.
Europe’s medicines watchdog said on Monday it had begun evaluating the use of Pfizer/BioNTech’s vaccine for 12 to 15-year-olds, after a similar request in the United States.
Vaccine authorization for children is seen as a crucial step towards achieving herd immunity.
Read more Region & World
Read More
Colombia president cuts ties with Israel over war on Gaza
Tens of millions of people in North America witness a total solar eclipse
US Senate passes bill to avert partial gov’t shutdown
WASHINGTON, DC — US biotech firm
Novavax said on Monday it had started clinical trials of its proposed
COVID-19 vaccine on children, in a program that will involve up to 3,000 adolescents aged 12–17.
Far fewer children have been sick with COVID-19 compared to adults, and most have mild to no symptoms, but they can be infected and spread the virus.
Novavax said the trials would test “the efficacy (and) safety” of the
vaccine, with participants receiving either the vaccine candidate or placebo in two doses, 21 days apart.
Participants will be monitored for up to two years after their injections.
The Novavax vaccine has not yet been authorized in any country, including for adults, but the company plans to file for emergency authorization in Britain “in the second quarter of 2021”, followed by in the United States.
Novavax announced at the end of January that clinical trials conducted in Britain involving 15,000 adults showed 89.3 percent efficacy.
The Novavax vaccine, which uses different technology from the doses already widely licensed around the world, is a protein-based vaccine engineered from the genetic sequence of the first strain of the coronavirus.
It can be stored at a temperature between 2–8°C.
Other vaccine companies including Moderna, Johnson & Johnson and Pfizer are also conducting trials in adolescents.
Europe’s medicines watchdog said on Monday it had begun evaluating the use of Pfizer/BioNTech’s vaccine for 12 to 15-year-olds, after a similar request in the United States.
Vaccine authorization for children is seen as a crucial step towards achieving herd immunity.
Read more Region & World
